U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07046975) titled 'Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone' on June 06.
Brief Summary: To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Bioavailability Heathy Volunteers
Intervention:
DRUG: Torsemide and Spironolactone tablet
Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet
DRUG: Torsemide Tablets and Spironolactone Ta...